Emergent BioSolutions announced a $56 million contract modification to supply ACAM2000® vaccine to the U.S. government.
The total projected sales for ACAM2000® vaccine and ancillary products exceed $120 million this year.
ACAM2000® is a single-dose vaccine approved for smallpox and mpox immunization in high-risk individuals.
Contract Modification
$56 million contract modification to supply ACAM2000® vaccine to the U.S. government.
Sales Projection
Total projected sales for ACAM2000® vaccine and ancillary products exceed $120 million this year.
Vaccine Approval
ACAM2000® is approved for active immunization against smallpox and mpox in high-risk individuals.
- The contract modification demonstrates Emergent's ongoing collaboration with the U.S. government for preparedness support.
- The sales projection of over $120 million signifies the importance of ACAM2000® vaccine in public health efforts.
Emergent BioSolutions' contract modification and sales projection for ACAM2000® vaccine highlight its commitment to public health preparedness and collaboration with government agencies.